Michele Lau, McKesson Corporation's Executive Vice President and Chief Legal Officer, executed a sale of common stock on February 11, 2026. The transaction comprised 303 shares sold at a price of $933.39 per share, with the total proceeds reported as $282,817.
Following that sale, Lau's direct holdings in McKesson total 5,972 shares. In addition to those directly held shares, Lau has an indirect interest amounting to 138.6376 shares through the McKesson Corporation 401(k) Retirement Savings Plan. The disposition was carried out under a plan that Lau previously adopted on November 26, 2024, and the sale was reported as compliant with Rule 10b5-1(c).
The insider transaction arrives against the backdrop of McKesson's fiscal third-quarter 2026 financial results. The company reported adjusted earnings per share of $9.34, ahead of the analyst consensus of $9.16. Revenue for the quarter reached $106.16 billion, modestly above the forecasted $105.87 billion.
Despite the better-than-expected earnings and revenue, McKesson's stock moved lower in aftermarket trading, reflecting a mixed investor response to the quarterly report. In the wake of the results, TD Cowen raised its price target for McKesson from $1,000 to $1,012 and maintained a Buy rating. The firm cited McKesson's performance in its Oncology & Manufacturer Solutions (O&M) and RxTS segments as factors supporting its revised target.
Together, the insider sale and the company report provide concurrent datapoints on executive liquidity and operational performance. The sale was executed under an established trading plan and the quarterly numbers indicate operational strength in specific segments, while market reaction and share price movement in aftermarket trading show investor responses were not uniformly positive.